bioAffinity Technologies, Inc. (BIAF) Company Overview

What does bioAffinity Technologies do?

bioAffinity Technologies, Inc. is a San Antonio-based diagnostics and biotechnology company listed on the Nasdaq Capital Market under BIAF. Its central commercial product is CyPath® Lung, a noninvasive laboratory-developed test intended to help physicians assess high-risk patients with small or indeterminate pulmonary nodules. The company describes its broader platform as flow cytometry combined with automated analysis informed by machine learning. That platform is also being explored for asthma, chronic obstructive pulmonary disease, and cancer therapeutics. The latest 2025 Form 10-K is the clearest source for the current business structure.

A commercial laboratory wrapped around a diagnostic platform

CyPath Lung is performed by Precision Pathology Laboratory Services, or PPLS, a wholly owned CAP-accredited and CLIA-certified laboratory. bioAffinity acquired the laboratory assets in September 2023, bringing testing operations, billing, histology services, and medical-director work inside the group. The PPLS acquisition announcement explains why today’s income statement contains both a proprietary diagnostic and conventional pathology revenue.

Why the lung-nodule decision point matters

The business is not trying to replace low-dose CT screening. It is positioned after imaging, when a physician must decide whether a suspicious nodule justifies biopsy, bronchoscopy, PET imaging, or continued surveillance. bioAffinity reports 92% sensitivity, 87% specificity, 99% negative predictive value, and 88% accuracy for patients with nodules under 20 millimeters in a disclosed clinical subset. Those measures matter because a balanced test must identify cancer while also reducing false positives and avoidable invasive procedures. The company’s official platform overview connects that clinical objective to its mission of improving early detection and lowering diagnostic burden.

How does bioAffinity Technologies make money?

The current model has one strategic revenue engine and several laboratory-supporting streams. Physicians order testing; the laboratory processes specimens and recognizes revenue when testing is complete and results are reported. Histology and medical-director services are recognized when the service is delivered. This makes revenue dependent on order volume, completed samples, payer collections, reimbursement, and the mix of proprietary versus conventional laboratory work.

Which revenue streams matter most?

What did the Q1 2026 mix look like?

What do the latest reported results show?

The latest complete financial statements are for the quarter ended March 31, 2026, while the freshest operating update covers CyPath Lung sales in Q2 2026. The two periods tell different but complementary stories: consolidated revenue remained below the prior year because management discontinued unprofitable pathology services, while proprietary-test adoption accelerated.

Q1 2026 financial snapshot

The company’s Q1 2026 results release also reported that CyPath Lung unit sales rose 146% and the number of ordering physician offices and clinics increased 69% year over year. Those are more informative commercialization indicators than consolidated revenue during a deliberate business-mix reset.

Cost structure, margins, and cash burn

The Q2 2026 sales update is encouraging but incomplete

The July 7, 2026 Q2 sales update also said physician offices ordering the test increased 155% year over year. This is the freshest evidence of adoption, but it does not yet provide Q2 revenue, gross economics, operating loss, or cash. Researchers should therefore treat it as an operating milestone rather than a substitute for the next Form 10-Q.

How did bioAffinity’s strategy evolve?

The company’s history is best understood as a sequence of de-risking steps: acquire technology, improve test performance, establish a laboratory route to market, bring the laboratory in-house, prune unattractive services, and launch broader clinical validation. Each step changed either control of the care pathway or the evidence needed for adoption.

Turning points that still shape the company

1. 2014
   bioAffinity began operations and concentrated resources on developing a noninvasive lung diagnostic. The long pre-revenue period created today’s accumulated deficit and dependence on external capital.
2. 2015
   An earlier fluorescent-microscopy study reported 81% accuracy, 77.9% sensitivity, and 65.7% specificity, pointing management toward full-sample analysis and automation.
3. 2022
   CyPath Lung entered commercial use as a laboratory-developed test, and the September IPO supplied capital for commercialization and public-company operations.
4. 2023
   Published validation strengthened the clinical case, while the September PPLS asset acquisition integrated the performing laboratory and added recurring pathology revenue.
5. 2025
   Management discontinued selected unprofitable pathology services. Consolidated revenue fell, but direct costs declined and CyPath Lung became a larger part of the mix.
6. 2026
   The first patient entered a longitudinal study designed for up to 2,063 patients across 17 sites, while Q1 and Q2 commercial sales accelerated.

Why owning PPLS changed the business model

Before integration, bioAffinity depended on a partner laboratory to validate, process, market, and sell the LDT. Ownership improves control over sample logistics, laboratory quality, billing data, turnaround, customer experience, and the commercialization feedback loop. It also exposes shareholders to laboratory staffing, payer collection, compliance, leases, and conventional pathology margins. The 2025 restructuring highlights this trade-off: vertical integration can support the proprietary test, but not every inherited service deserves capital.

What gives CyPath Lung a competitive position?

bioAffinity’s claimed advantage combines patient convenience, balanced clinical performance, familiar laboratory technology, automated interpretation, and potential healthcare-cost savings. The defensibility is not the same as a consumer brand or a large installed base. It depends on evidence, reimbursement, physician trust, laboratory execution, intellectual property, and successful placement in the post-CT diagnostic pathway.

Clinical performance and patient experience

Operational simplicity can be an advantage

The test uses established flow-cytometry methods, widely available reagents, and automated data acquisition and analysis. That matters because commercialization is easier when a test does not rely on unstable genetic material or highly bespoke equipment. The company also points to a Medicare billing code and published economic work estimating potential savings of $2,773 per Medicare patient and $6,460 per privately insured patient with a positive lung-cancer screen. These figures are modeled savings, not realized company revenue, but they help frame the value proposition for physicians and payers.

Clinical validation and platform optionality define the growth case

The growth case has two layers. The first is straightforward: more physicians order CyPath Lung, more samples are successfully completed, reimbursement converts those tests into cash, and the proprietary product becomes a larger percentage of laboratory revenue. The second is optionality from additional diagnostics and therapeutics, which may be scientifically interesting but is far less mature.

The longitudinal trial is the most important evidence program

The study began enrolling in March 2026 and is designed for up to 2,063 high-risk patients with nodules from 6 millimeters to under 30 millimeters at 17 VA, military, academic, and private sites. Patients may be followed for as long as two years until a cancer or noncancer diagnosis is established. Three federally connected collection sites receive support associated with the Murtha Cancer Center Research Program. A successful multicenter prospective dataset could address physicians who hesitate to order an LDT without larger longitudinal evidence.

Asthma, COPD, and therapeutics add upside—but also focus risk

For valuation work, these programs should not be treated like mature products. They are best viewed as probability-weighted options whose value depends on reproducibility, patents, partners, development costs, and regulatory pathways. The more urgent strategic question is whether management can protect CyPath commercialization from dilution of attention and cash.

How financially strong is bioAffinity Technologies?

Financial strength is the company’s central constraint. bioAffinity has revenue and increasing CyPath adoption, but it is not self-funding. At March 31, 2026, cash was $3.098 million, current assets were $4.341 million, total assets were $7.945 million, stockholders’ equity was $3.661 million, and accumulated deficit was $72.185 million. Operating cash use of $3.227 million during Q1 consumed roughly half of the $6.450 million cash balance held at December 31, 2025.

Liquidity and going-concern risk

The Q1 2026 Form 10-Q states that substantial doubt existed about the company’s ability to continue as a going concern for at least twelve months after issuance. This is not an abstract accounting note. It means commercialization milestones must be considered alongside the timing, price, and dilution of future financing.

Financing and capital allocation dominate the equity story

The June 2026 financing announcement illustrates the practical trade-off. The proceeds extend runway, but issuing 4.0 million shares or equivalents was substantial against the March share base. A DCF cannot ignore this financing cycle: enterprise value may rise with commercial success while per-share value is diluted if capital is repeatedly raised at low prices.

Who owns bioAffinity stock, and how is it governed?

bioAffinity has a one-class common-stock structure in the disclosed ownership table, with management and directors holding a relatively small aggregate stake. That means governance is not dominated by a founder with majority voting control. However, dispersed ownership does not eliminate influence: financing counterparties, warrant holders, and investors participating in repeated offerings can materially affect the capital structure.

Insider ownership is modest

These figures come from the 2026 definitive proxy statement, based on 4,498,675 common shares outstanding at the March 13, 2026 record date. The proxy reported nine directors and current executive officers as a group with 2.68% beneficial ownership.

Leadership and board composition

What risks and opportunities could change bioAffinity’s outlook?

The opportunity is unusually easy to state: convert improving physician adoption into a repeatable national diagnostic business, support it with multicenter evidence, preserve reimbursement, and use the same platform selectively in adjacent lung diseases. The risk is that commercial progress may arrive more slowly than cash is consumed. Competition, payer behavior, regulation, clinical execution, and financing terms can each interrupt the path.

Which variables deserve the closest monitoring?

What is the key takeaway from bioAffinity Technologies analysis?

bioAffinity is a commercialization-stage diagnostics company rather than a diversified profitable healthcare business. The central asset is CyPath Lung, supported by a vertically integrated laboratory, disclosed small-nodule performance, growing physician adoption, and a prospective multicenter validation strategy. Q1 2026 CyPath revenue rose 114%, unit sales rose 146%, and Q2 sales volume increased more than 200% year over year. Those signals show that the product is gaining use.

The counterweight is financial. Q1 2026 net loss was $3.631 million, operating cash use was $3.227 million, and management reported substantial doubt about continued operations without additional capital. The June 2026 offering supplied $3.2 million gross but was highly dilutive relative to the March share base. Therefore, the valuation question is not simply whether CyPath grows. It is whether revenue growth, reimbursement, laboratory economics, and trial evidence can improve quickly enough to reduce repeated financing before per-share economics are overwhelmed.